Findings seen in patients with chronic pouchitis after ileal pouch-anal anastomosis for ulcerative colitis<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, March 31, 2023 (HealthDay News) — For patients with chronic pouchitis after undergoing restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis, treatment with vedolizumab is more effective than placebo for inducing remission, according to a study published in the March 30 issue of the New England Journal of Medicine<\/em>.<\/p>\n Simon Travis, D.Phil., from the University of Oxford in the United Kingdom, and colleagues conducted a phase 4 double-blind, randomized trial to assess vedolizumab in adults in whom chronic pouchitis developed after undergoing IPAA for ulcerative colitis. A total of 102 patients were randomly assigned to vedolizumab 300 mg or placebo on day 1 and at weeks 2, 6, 14, 22, and 30 (51 patients in each group). Patients also received concomitant ciprofloxacin from weeks 1 to 4.<\/p>\n The researchers found the incidence of modified Pouchitis Disease Activity Index (mPDAI)-defined remission was 31 and 10 percent with vedolizumab and placebo, respectively, at week 14. There were also differences in favor of vedolizumab versus placebo in mPDAI-defined remission at week 34, mPDAI-defined response at week 14 and week 34, and PDAI-defined remission at weeks 14 and 34. Serious adverse events occurred in 6 and 8 percent of patients in the vedolizumab and placebo groups, respectively.<\/p>\n “Among patients who had chronic pouchitis after undergoing IPAA for ulcerative colitis, treatment with vedolizumab was more effective than placebo in the induction of remission,” the authors write.<\/p>\n The study was funded by Takeda, the manufacturer of vedolizumab.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n